Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) has entered into a technology development partnership with Novo Nordisk in cell therapy. The collaboration aims to support the development of next-generation off-the-shelf cell therapy products for clinical development and potential commercialization.
Novo Nordisk will provide funding for technology development activities at Evotec's R&D site in Göttingen, Germany, and at Evotec's certified cell therapy manufacturing facility in Modena, Italy. Novo Nordisk has an option to obtain exclusive rights to use the collaboration results for a pre-defined therapeutic area.
Evotec will receive R&D funding, an undisclosed upfront payment, and potential milestone and royalty payments. The partnership focuses on developing advanced technologies to support stem cell-based therapies, which have shown promise in becoming functional cures for many diseases.
Evotec SE (Borsa di Francoforte: EVT, NASDAQ: EVO) ha avviato una partnership per lo sviluppo tecnologico con Novo Nordisk nel campo della terapia cellulare. La collaborazione mira a supportare lo sviluppo di prodotti di terapia cellulare di nuova generazione pronti all'uso per lo sviluppo clinico e la potenziale commercializzazione.
Novo Nordisk fornirà finanziamenti per le attività di sviluppo tecnologico presso il sito di R&S di Evotec a Göttingen, Germania, e presso l'impianto certificato di produzione di terapia cellulare di Evotec a Modena, Italia. Novo Nordisk ha la possibilità di ottenere diritti esclusivi per utilizzare i risultati della collaborazione in un'area terapeutica predefinita.
Evotec riceverà finanziamenti per la R&S, un pagamento anticipato non divulgato e potenziali pagamenti legati a traguardi e royalty. La partnership si concentra sullo sviluppo di tecnologie avanzate a supporto delle terapie a base di cellule staminali, che hanno dimostrato di avere un potenziale per diventare cure funzionali per molte malattie.
Evotec SE (Bolsa de Frankfurt: EVT, NASDAQ: EVO) ha entrado en una asociación de desarrollo tecnológico con Novo Nordisk en terapia celular. La colaboración tiene como objetivo apoyar el desarrollo de productos de terapia celular de próxima generación listos para usar para el desarrollo clínico y la posible comercialización.
Novo Nordisk proporcionará financiación para actividades de desarrollo tecnológico en el sitio de I+D de Evotec en Göttingen, Alemania, y en la instalación de fabricación de terapia celular certificada de Evotec en Modena, Italia. Novo Nordisk tiene la opción de obtener derechos exclusivos para utilizar los resultados de la colaboración en un área terapéutica predefinida.
Evotec recibirá financiación de I+D, un pago inicial no revelado y posibles pagos por hitos y regalías. La asociación se centra en el desarrollo de tecnologías avanzadas para apoyar terapias basadas en células madre, que han mostrado prometedores resultados en convertirse en curas funcionales para muchas enfermedades.
Evotec SE (프랑크푸르트 증권 거래소: EVT, NASDAQ: EVO)는 세포 치료 분야에서 Novo Nordisk와 기술 개발 파트너십을 체결했습니다. 이 협력은 임상 개발 및 잠재적 상용화를 위한 차세대 오프더셀프 세포 치료 제품의 개발을 지원하는 것을 목표로 합니다.
Novo Nordisk는 독일 괴팅겐에 있는 Evotec의 연구개발(R&D) 센터 및 이탈리아 모데나에 있는 Evotec의 인증된 세포 치료제 제조 시설에서 기술 개발 활동을 위한 자금을 제공합니다. Novo Nordisk는 협력 결과를 미리 정의된 치료 영역에 대해 독점적 권리를 획득할 수 있는 선택권을 가지고 있습니다.
Evotec는 연구개발 자금, 공개되지 않은 선불금, 그리고 잠재적인 이정표 및 로열티 지급을 받을 것입니다. 이 파트너십은 많은 질병에 대한 기능적 치료로 발전할 가능성이 보이는 줄기세포 기반 치료법을 지원하기 위한 첨단 기술 개발에 중점을 두고 있습니다.
Evotec SE (Bourse de Francfort : EVT, NASDAQ : EVO) a conclu un partenariat de développement technologique avec Novo Nordisk dans le domaine de la thérapie cellulaire. Cette collaboration vise à soutenir le développement de produits de thérapie cellulaire de nouvelle génération prêts à l'emploi pour le développement clinique et la commercialisation potentielle.
Novo Nordisk fournira un financement pour les activités de développement technologique sur le site R&D d'Evotec à Göttingen, en Allemagne, et dans l'installation de fabrication de thérapie cellulaire certifiée d'Evotec à Modène, en Italie. Novo Nordisk a la possibilité d'obtenir des droits exclusifs pour utiliser les résultats de la collaboration dans un domaine thérapeutique prédéfini.
Evotec recevra un financement pour la R&D, un paiement initial non divulgué et des paiements d'étapes et de redevances potentiels. Le partenariat se concentre sur le développement de technologies avancées pour soutenir les thérapies basées sur les cellules souches, qui se sont révélées prometteuses comme cures fonctionnelles pour de nombreuses maladies.
Evotec SE (Frankfurter Wertpapierbörse: EVT, NASDAQ: EVO) hat eine Technologie-Entwicklungspartnerschaft mit Novo Nordisk im Bereich der Zelltherapie gegründet. Die Zusammenarbeit zielt darauf ab, die Entwicklung von Produkten der nächsten Generation für Zelltherapien, die sofort einsatzbereit sind, für die klinische Entwicklung und die potenzielle Kommerzialisierung zu unterstützen.
Novo Nordisk wird Finanzierung für technische Entwicklungsaktivitäten an Evotecs F&E-Standort in Göttingen, Deutschland, sowie an Evotecs zertifizierter Produktionsstätte für Zelltherapia in Modena, Italien, bereitstellen. Novo Nordisk hat die Option, exklusive Rechte zur Nutzung der Zusammenarbeitsergebnisse in einem vorab definierten therapeutischen Bereich zu erwerben.
Evotec wird F&E-Finanzierung, eine nicht offengelegte Vorauszahlung und mögliche Meilenstein- und Lizenzzahlungen erhalten. Die Partnerschaft konzentriert sich auf die Entwicklung fortschrittlicher Technologien zur Unterstützung von Stammzelltherapien, die vielversprechende Ergebnisse aufweisen und funktionale Heilungen für viele Krankheiten darstellen könnten.
- Partnership with Novo Nordisk, a major player in the pharmaceutical industry
- Funding for technology development activities at Evotec's R&D sites
- Potential for exclusive rights for Novo Nordisk in a pre-defined therapeutic area
- Evotec to receive R&D funding, upfront payment, and potential milestone and royalty payments
- Focus on developing advanced technologies for stem cell-based therapies
- None.
Insights
This partnership between Evotec and Novo Nordisk is a significant development in the cell therapy space. Evotec's expertise in stem cell-based therapies, combined with Novo Nordisk's funding and potential commercialization capabilities, could accelerate the development of next-generation off-the-shelf cell therapies.
Key points to consider:
- Evotec receives R&D funding, an upfront payment and potential milestone and royalty payments, which could positively impact their financials.
- The collaboration leverages Evotec's facilities in Göttingen and Modena, potentially enhancing their capabilities and value proposition.
- Novo Nordisk's option for exclusive rights in a pre-defined therapeutic area could lead to long-term revenue streams for Evotec if successful.
- The focus on off-the-shelf cell therapies addresses a important need in the market for more accessible and cost-effective treatments.
While the immediate financial impact may be , this partnership positions Evotec well in the rapidly growing cell therapy market, potentially leading to significant long-term value creation for investors.
This collaboration marks a significant step forward in the development of stem cell-based therapies. The partnership combines Evotec's technological expertise with Novo Nordisk's resources and clinical development capabilities, potentially accelerating the path to market for novel cell therapies.
Key aspects to consider:
- The focus on off-the-shelf cell therapies could revolutionize treatment accessibility and reduce manufacturing costs.
- Evotec's certified cell therapy manufacturing facility in Modena is a important asset, enabling scalable production for clinical trials and potential commercialization.
- The collaboration's emphasis on "tailor-made" therapies suggests a move towards more personalized medicine approaches.
- The potential for these therapies to become "functional cures" in multiple disease areas could significantly impact patient outcomes and healthcare economics.
While specific therapeutic areas aren't disclosed, this partnership has the potential to yield groundbreaking advancements in cell therapy, possibly leading to first-in-class treatments for various diseases.
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies
HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on development of advanced technologies in support thereof.
Under the collaboration agreement, Novo Nordisk will provide funding for technology development activities at Evotec's R&D site in Göttingen, Germany and at Evotec's certified cell therapy manufacturing facility in Modena, Italy. Novo Nordisk has an option to obtain exclusive rights to utilise the results of the collaboration for a pre-defined therapeutic area. Evotec receives R&D funding, an undisclosed upfront and possible milestone and royalty payments.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Cell therapies have already proven to be highly effective and have the potential to become functional cures in many disease areas. Stem cell-based cell therapy is a promising approach to modulate and scale cell therapies to ultimately provide tailor-made, off-the-shelf cell therapies at reasonable costs. Together with Novo Nordisk, we are confident to be able to generate novel and robust technologies that will help deliver on the promise of stem cell-based therapies."
Dr Joachim Fruebis, Corporate Vice President, Cell Therapy R&D, at Novo Nordisk, added: "We are excited to join forces with Evotec on our cell therapy initiatives. We hope that this collaboration will enable us to bring cutting-edge, stem cell-based therapies to patients more efficiently. By integrating our strengths, we are setting the stage for significant breakthroughs to more efficiently advance our cell therapies. This partnership holds great promise, and I am confident it will lead to significant advancements in realising our full potential "
About Cell Therapy at Evotec
Cell therapy, one of the most promising regenerative medicine approaches, replaces a patient's missing or broken cells with functioning cells from a range of different sources, either from a donor, from the patient's own material, or from stem cells. Stem cell research has opened up an almost unlimited source of consistent-quality material for such cell therapies. At the same time, differentiating cell therapies from a single validated source circumvents critical risks of contamination associated with administering both donor and patient cell material.
Building on Evotec's industrialised induced pluripotent stem cell ("iPSC") platform, Evotec has built up a proprietary cell therapy with broad and deep capacity and capabilities. Evotec's initiatives include proprietary and partnered cell types currently in pre-clinical development for a broad range of indications including diabetes, oncology, cardiology, and ophthalmology.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the purpose of the partnership between Evotec and Novo Nordisk?
What financial benefits will Evotec (EVO) receive from this partnership?
Where will the technology development activities take place for this Evotec (EVO) partnership?
What type of therapies are Evotec (EVO) and Novo Nordisk focusing on in this collaboration?
